Epithelial tumor, invasion and stroma

Annals of Dermatology

Volumn 23, Issue 2, 2011, Pages 125-131

  Furue, Masutaka ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Fibroblast; Invasion; Stroma; Tumor

Indexed keywords

EID: 79958739240     PISSN: 10139087     EISSN: None     Source Type: Journal    
DOI: 10.5021/ad.2011.23.2.125     Document Type: Review

References (42)

1. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004;5:816-826. (Pubitemid 39336275)
2. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006;12:895-904. (Pubitemid 44175140)
3. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009;119:1429-1437.
4. Miyazono K. Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci 2009;85:314-323.
5. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell 2009;139:871-890.
6. Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000;2:76-83.
7. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998;392:190-193. (Pubitemid 28162793)
8. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-687. (Pubitemid 35283958)
9. Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell 2006;127:679-695. (Pubitemid 44781029)
10. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47. (Pubitemid 37328806)
11. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732. (Pubitemid 37328811)
12. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006;3:e47.
13. Lining X, Uchi H, Hayashida S, Tsuji G, Kido M, Nakahara T, et al. Expression of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2alpha with progression of keratinocytic neoplasms. J Dermatol Sci 2009;56:135-136.
14. Chen SY, Takeuchi S, Moroi Y, Hayashida S, Kido M, Chen SJ, et al. Overexpression of phosphorylated-ATF2 and STAT3 in cutaneous squamous cell carcinoma, Bowen's disease and basal cell carcinoma. J Dermatol Sci 2008;51:210-215.
15. Lin N, Moroi Y, Uchi H, Fukiwake N, Dainichi T, Takeuchi S, et al. Significance of the expression of phosphorylated-STAT3, -Akt, and -ERK1/2 in several tumors of the epidermis. J Dermatol Sci 2007;48:71-73. (Pubitemid 47284806)
16. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003;425: 307-311. (Pubitemid 37158407)
17. Lorusso G, Rüegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 2008;130:1091-1103.
18. Hanna E, Quick J, Libutti SK. The tumour microenvironment: a novel target for cancer therapy. Oral Dis 2009;15:8-17.
19. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007;449:419-426. (Pubitemid 47509552)
20. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010;22:231-237.
21. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003;3: 362-374. (Pubitemid 37328856)
22. Balkwill F. Chemokine biology in cancer. Semin Immunol 2003;15:49-55. (Pubitemid 36092178)
23. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 2005;6:56-68. (Pubitemid 40064899)
24. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-925. (Pubitemid 37493640)
25. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004;432:332-337. (Pubitemid 39551661)
26. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, et al. Mesenchymal stem cell transition to tumorassociated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009;4:e4992.
27. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-899.
28. Eck SM, Côté AL, Winkelman WD, Brinckerhoff CE. CXCR4 and matrix metalloproteinase-1 are elevated in breast carcinoma-associated fibroblasts and in normal mammary fibroblasts exposed to factors secreted by breast cancer cells. Mol Cancer Res 2009;7:1033-1044.
29. Kleer CG, Bloushtain-Qimron N, Chen YH, Carrasco D, Hu M, Yao J, et al. Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clin Cancer Res 2008;14:5357-5367.
30. Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 1996;271:12511-12516. (Pubitemid 26160923)
31. Quintanilla-Dieck MJ, Codriansky K, Keady M, Bhawan J, Runger TM. Cathepsin K in melanoma invasion. J Invest Dermatol 2008;128:2281-2288.
32. Cordes C, Bartling B, Simm A, Afar D, Lautenschlager C, Hansen G, et al. Simultaneous expression of Cathepsins B and K in pulmonary adenocarcinomas and squamous cell carcinomas predicts poor recurrence-free and overall survival. Lung Cancer 2009;64:79-85.
33. Stimler-Gerard NP. Neutral endopeptidase-like enzyme controls the contractile activity of substance P in guinea pig lung. J Clin Invest 1987;79:1819-1825. (Pubitemid 17117290)
34. Albrecht M, Gillen S, Wilhelm B, Doroszewicz J, Aumüller G. Expression, localization and activity of neutral endopeptidase in cultured cells of benign prostatic hyperplasia and prostate cancer. J Urol 2002;168:336-342. (Pubitemid 34640853)
35. Kesse-Adu R, Shousha S. Myoepithelial markers are expressed in at least 29% of oestrogen receptor negative invasive breast carcinoma. Mod Pathol 2004;17:646-652. (Pubitemid 38715486)
36. Ogawa H, Iwaya K, Izumi M, Kuroda M, Serizawa H, Koyanagi Y, et al. Expression of CD10 by stromal cells during colorectal tumor development. Hum Pathol 2002; 33:806-811. (Pubitemid 34983101)
37. Xie LN, Uchi H, Hayashida S, Kido M, Takeuchi S, Takahara M, et al. Stromal CD10 expression is correlated with invasiveness and proliferation of extramammary Paget disease. Br J Dermatol 2008;158:1389-1391. (Pubitemid 351692870)
38. Takahara M, Chen S, Kido M, Takeuchi S, Uchi H, Tu Y, et al. Stromal CD10 expression, as well as increased dermal macrophages and decreased Langerhans cells, are associated with malignant transformation of keratinocytes. J Cutan Pathol 2009;36:668-674.
39. Muangman P, Tamura RN, Muffley LA, Isik FF, Scott JR, Xie C, et al. Substance P enhances wound closure in nitric oxide synthase knockout mice. J Surg Res 2009;153:201-209.
40. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-444.
41. Waldner MJ, Neurath MF. Colitis-associated cancer: the role of T cells in tumor development. Semin lmmunopathol 2009;31:249-256.
42. Nickoloff BJ, Ben-Neriah Y, Pikarsky E. Inflammation and cancer: is the link as simple as we think? J Invest Dermatol 2005;124:x-xiv. (Pubitemid 40847392)